Massachusetts General Hospital performed a groundbreaking surgery on 67-year-old Tim Andrews, who had been living with a genetically engineered pig kidney for nearly nine months. The organ was designed to address the shortage of human donor kidneys and provide a solution to the millions of people waiting for a transplant.
Andrews received the pig kidney in January after being on dialysis for over two years due to end-stage kidney disease. His rare blood type made him an ideal candidate for the transplant, which was performed by Leonardo Riella, medical director for kidney transplantation at Mass General.
The pig kidney functioned well initially and was able to support Andrews' life, but its immune-rejection led surgeons to remove it on October 23. Although Andrews will now resume dialysis, eGenesis, the biotech company that provided the genetically engineered pig kidney, considers the transplant a success. "Cross-species transplantation has been a goal for centuries that has only recently become possible due to decades of research and the convergence of enabling technologies," said the company in a statement.
This surgery marks an important milestone in the field of organ transplantation, as it demonstrates the feasibility of using genetically engineered pig organs in humans. The success of this transplant paves the way for future experiments with other organs, such as hearts, which have also been explored but with limited success so far.
Andrews' experience shows that genetic editing can make animal organs compatible with human bodies, and his case has sparked interest among scientists to continue exploring the potential of cross-species transplantation. The hospital plans to carry out another genetically edited pig kidney transplant before the end of the year, which could lead to more breakthroughs in the field of organ transplantation.
The shortage of human donor kidneys remains a pressing issue, with nearly 90,000 people waiting for a transplant in the US alone. This shortage has led scientists to explore alternative sources, such as genetically engineered pig organs, which could potentially provide a solution to this crisis. While there are still challenges to be addressed, Andrews' surgery offers hope that future transplants may become more accessible and successful.
Andrews received the pig kidney in January after being on dialysis for over two years due to end-stage kidney disease. His rare blood type made him an ideal candidate for the transplant, which was performed by Leonardo Riella, medical director for kidney transplantation at Mass General.
The pig kidney functioned well initially and was able to support Andrews' life, but its immune-rejection led surgeons to remove it on October 23. Although Andrews will now resume dialysis, eGenesis, the biotech company that provided the genetically engineered pig kidney, considers the transplant a success. "Cross-species transplantation has been a goal for centuries that has only recently become possible due to decades of research and the convergence of enabling technologies," said the company in a statement.
This surgery marks an important milestone in the field of organ transplantation, as it demonstrates the feasibility of using genetically engineered pig organs in humans. The success of this transplant paves the way for future experiments with other organs, such as hearts, which have also been explored but with limited success so far.
Andrews' experience shows that genetic editing can make animal organs compatible with human bodies, and his case has sparked interest among scientists to continue exploring the potential of cross-species transplantation. The hospital plans to carry out another genetically edited pig kidney transplant before the end of the year, which could lead to more breakthroughs in the field of organ transplantation.
The shortage of human donor kidneys remains a pressing issue, with nearly 90,000 people waiting for a transplant in the US alone. This shortage has led scientists to explore alternative sources, such as genetically engineered pig organs, which could potentially provide a solution to this crisis. While there are still challenges to be addressed, Andrews' surgery offers hope that future transplants may become more accessible and successful.